{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:47:05Z","timestamp":1782989225595,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10157-025-02678-9","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T02:31:48Z","timestamp":1744770708000},"page":"1200-1211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systolic blood pressure is associated with early and long-term changes in renal function in patients with dapagliflozin-treated moderate-to-advanced chronic kidney disease"],"prefix":"10.1007","volume":"29","author":[{"given":"Katsunori","family":"Yanai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-2478","authenticated-orcid":false,"given":"Keiji","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhisa","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyonori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Ookawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"2678_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/ijms241713381","volume":"24","author":"J Su","year":"2023","unstructured":"Su J, Luo Y, Hu S, Tang L, Ouyang S. Advances in research on type 2 diabetes mellitus targets and therapeutic agents. Int J Mol Sci. 2023;24:17. https:\/\/doi.org\/10.3390\/ijms241713381.","journal-title":"Int J Mol Sci"},{"key":"2678_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1530\/EC-23-0005","volume":"12","author":"MC Thomas","year":"2023","unstructured":"Thomas MC, Neuen BL, Twigg SM, Cooper ME, Badve SV. SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review. Endocr Connect. 2023;12:8. https:\/\/doi.org\/10.1530\/EC-23-0005.","journal-title":"Endocr Connect"},{"key":"2678_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ijms22094441","volume":"22","author":"G Leoncini","year":"2021","unstructured":"Leoncini G, Russo E, Bussalino E, Barnini C, Viazzi F, Pontremoli R. SGLT2is and renal protection: from biological mechanisms to real-world clinical benefits. Int J Mol Sci. 2021;22:9. https:\/\/doi.org\/10.3390\/ijms22094441.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2678_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/ckj\/sfac189","volume":"16","author":"Z Kalay","year":"2023","unstructured":"Kalay Z, Sahin OE, Copur S, Danaci S, Ortiz A, Yau K, et al. SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence. Clin Kidney J. 2023;16(1):52\u201360. https:\/\/doi.org\/10.1093\/ckj\/sfac189.","journal-title":"Clin Kidney J"},{"issue":"3","key":"2678_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7326\/M22-2904","volume":"176","author":"SD Navaneethan","year":"2023","unstructured":"Navaneethan SD, Zoungas S, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, et al. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023;176(3):381\u20137. https:\/\/doi.org\/10.7326\/M22-2904.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2678_CR6","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int. 2022;102(5):990\u20139. https:\/\/doi.org\/10.1016\/j.kint.2022.06.013.","journal-title":"Kidney Int"},{"issue":"15","key":"2678_CR7","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"11","key":"2678_CR8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","volume":"9","author":"N Jongs","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):755\u201366. https:\/\/doi.org\/10.1016\/S2213-8587(21)00243-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2678_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12325-021-01994-2","volume":"39","author":"CW Mende","year":"2022","unstructured":"Mende CW. Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape. Adv Ther. 2022;39(1):148\u201364. https:\/\/doi.org\/10.1007\/s12325-021-01994-2.","journal-title":"Adv Ther"},{"key":"2678_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/jcm11195622","volume":"11","author":"JJ Gorgojo-Martinez","year":"2022","unstructured":"Gorgojo-Martinez JJ, Brito-Sanfiel M, Anton-Bravo T, Galdon Sanz-Pastor A, Wong-Cruz J, Gargallo Fernandez MA. Predictive factors of renal function decline in patients with type 2 diabetes treated with canagliflozin in the real-wecan study. J Clin Med. 2022;11:19. https:\/\/doi.org\/10.3390\/jcm11195622.","journal-title":"J Clin Med"},{"issue":"6","key":"2678_CR11","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/jdi.13064","volume":"10","author":"H Miyoshi","year":"2019","unstructured":"Miyoshi H, Kameda H, Yamashita K, Nakamura A, Kurihara Y. Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes. J Diabetes Investig. 2019;10(6):1510\u20137. https:\/\/doi.org\/10.1111\/jdi.13064.","journal-title":"J Diabetes Investig"},{"issue":"11","key":"2678_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020237","volume":"10","author":"Y Xie","year":"2021","unstructured":"Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Al-Aly Z. Clinical implications of estimated glomerular filtration rate dip following sodium-glucose cotransporter-2 inhibitor initiation on cardiovascular and kidney outcomes. J Am Heart Assoc. 2021;10(11): e020237. https:\/\/doi.org\/10.1161\/JAHA.120.020237.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2678_CR13","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","volume":"99","author":"M Oshima","year":"2021","unstructured":"Oshima M, Jardine MJ, Agarwal R, Bakris G, Cannon CP, Charytan DM, et al. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int. 2021;99(4):999\u20131009. https:\/\/doi.org\/10.1016\/j.kint.2020.10.042.","journal-title":"Kidney Int"},{"issue":"1","key":"2678_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10157-022-02277-y","volume":"27","author":"R Shibata","year":"2023","unstructured":"Shibata R, Taguchi K, Kaida Y, Fukami K. Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus. Clin Exp Nephrol. 2023;27(1):44\u201353. https:\/\/doi.org\/10.1007\/s10157-022-02277-y.","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"2678_CR15","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/ndt\/gfae027","volume":"39","author":"M Kanbay","year":"2024","unstructured":"Kanbay M, Copur S, Bakir CN, Covic A, Ortiz A, Tuttle KR. Glomerular hyperfiltration as a therapeutic target for CKD. Nephrol Dial Transplant. 2024;39(8):1228\u201338. https:\/\/doi.org\/10.1093\/ndt\/gfae027.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"2678_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41581-023-00748-3","volume":"19","author":"JS Lees","year":"2023","unstructured":"Lees JS, Mark PB. GFR slope as a surrogate marker for future kidney failure. Nat Rev Nephrol. 2023;19(10):625\u20136. https:\/\/doi.org\/10.1038\/s41581-023-00748-3.","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"2678_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17446651.2022.2099373","volume":"17","author":"Y Kurata","year":"2022","unstructured":"Kurata Y, Nangaku M. Dapagliflozin for the treatment of chronic kidney disease. Expert Rev Endocrinol Metab. 2022;17(4):275\u201391. https:\/\/doi.org\/10.1080\/17446651.2022.2099373.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"6","key":"2678_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2678_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/sj.jhh.1001307","volume":"16","author":"T Tanaka","year":"2002","unstructured":"Tanaka T, Okamura T, Miura K, Kadowaki T, Ueshima H, Nakagawa H, et al. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. J Hum Hypertens. 2002;16(2):97\u2013103. https:\/\/doi.org\/10.1038\/sj.jhh.1001307.","journal-title":"J Hum Hypertens"},{"issue":"12","key":"2678_CR20","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","volume":"18","author":"HN Reich","year":"2007","unstructured":"Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto GR. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177\u201383. https:\/\/doi.org\/10.1681\/ASN.2007050526.","journal-title":"J Am Soc Nephrol"},{"key":"2678_CR21","doi-asserted-by":"publisher","unstructured":"Japanese Society of N. Essential points from evidence-based clinical practice guidelines for chronic kidney disease 2018. Clin Exp Nephrol. 2019;23(1):1\u201315. https:\/\/doi.org\/10.1007\/s10157-018-1648-1.","DOI":"10.1007\/s10157-018-1648-1"},{"issue":"6","key":"2678_CR22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","volume":"146","author":"C Adamson","year":"2022","unstructured":"Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, et al. Initial decline (Dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation. 2022;146(6):438\u201349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.058910.","journal-title":"Circulation"},{"key":"2678_CR23","doi-asserted-by":"publisher","DOI":"10.1159\/000538589","author":"Y Miyaoka","year":"2024","unstructured":"Miyaoka Y, Moriyama T, Saito S, Rinno S, Kato M, Tsujimoto R, et al. Larger degree of renal function decline in CKD is a favorable factor for the attenuation of eGFR slope worsening by SGLT2 inhibitors: a retrospective observational study. Nephron. 2024. https:\/\/doi.org\/10.1159\/000538589.","journal-title":"Nephron"},{"issue":"7","key":"2678_CR24","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1111\/dom.15611","volume":"26","author":"T Kanaoka","year":"2024","unstructured":"Kanaoka T, Wakui H, Yano Y, Nagasu H, Kanegae H, Nangaku M, et al. Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: the Japan Chronic Kidney Disease Database. Diabetes Obes Metab. 2024;26(7):2905\u201314. https:\/\/doi.org\/10.1111\/dom.15611.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2678_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41440-020-0426-0","volume":"43","author":"K Kohagura","year":"2020","unstructured":"Kohagura K, Yamasaki H, Takano H, Ohya Y, Seino Y. Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes. Hypertens Res. 2020;43(9):876\u201383. https:\/\/doi.org\/10.1038\/s41440-020-0426-0.","journal-title":"Hypertens Res"},{"issue":"5","key":"2678_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587\u201397. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005081.","journal-title":"Circulation"},{"issue":"10","key":"2678_CR27","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/nep.14207","volume":"28","author":"M Murakoshi","year":"2023","unstructured":"Murakoshi M, Kobayashi T, Kihara M, Ueda S, Suzuki Y, Gohda T. The proteinuria-lowering effects of dapagliflozin are associated with an initial decline in estimated glomerular filtration rate in patients with chronic kidney disease. Nephrology (Carlton). 2023;28(10):540\u20137. https:\/\/doi.org\/10.1111\/nep.14207.","journal-title":"Nephrology (Carlton)"},{"issue":"7","key":"2678_CR28","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1097\/HJH.0000000000002050","volume":"37","author":"A Piperidou","year":"2019","unstructured":"Piperidou A, Sarafidis P, Boutou A, Thomopoulos C, Loutradis C, Alexandrou ME, et al. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37(7):1334\u201343. https:\/\/doi.org\/10.1097\/HJH.0000000000002050.","journal-title":"J Hypertens"},{"issue":"7","key":"2678_CR29","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","volume":"8","author":"DZI Cherney","year":"2020","unstructured":"Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020;8(7):582\u201393. https:\/\/doi.org\/10.1016\/S2213-8587(20)30162-5.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02678-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02678-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02678-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:03:11Z","timestamp":1758045791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02678-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2678"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02678-9","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study conformed to the Declaration of Helsinki and was approved by the Ethics Committee of Jichi Medical University (no. S23-148).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical study approval"}},{"value":"Owing to the investigation\u2019s retrospective nature, written informed consent was not necessary. Information about this study, including the patients\u2019 rights to opt out, is available on the Medical Center's website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}